May 22, 2024
Sjogren’s Syndrome Market

Sjogren’s Syndrome Market Is Expected To Be Flourished By Rising Investments In R&D Of Novel Therapies

Sjogren’s syndrome is an autoimmune disease characterized by dry eyes and dry mouth due to the immune system attacking and destroying the glands that produce tears and saliva. It is estimated that around 4 million Americans are affected by Sjogren’s syndrome and symptoms may also include fatigue, dry skin, dry nose and throat, joint pain and swelling. Currently, there is no cure for Sjogren’s syndrome and treatment focuses on relieving symptoms which include artificial tears, corticosteroids, plaquenil and immunosuppressive drugs. The global Sjogren’s syndrome market is estimated to be valued at US $1.8 billion in 2023 and is expected to exhibit a CAGR of 7.1% over the forecast period 2023-2031, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics

Rising investments in R&D of novel therapies for Sjogren’s syndrome is expected to drive the market growth over the forecast period. For instance, Mallinckrodt Pharmaceuticals is conducting phase III clinical trial evaluating activismab for primary Sjogren’s syndrome treatment. Similarly, ImmuPharma has discovered Lupuzor/P140 peptide that blocks T-cell activation and is currently being evaluated in phase II clinical trial. Furthermore, increasing awareness about early diagnosis and treatment of Sjogren’s syndrome signs and symptoms is another factor fueling the market growth. However, challenges in disease diagnosis due to non-specific presenting symptoms is a major factor hindering the market growth.

Segment Analysis

The global Sjogren’s Syndrome market is dominated by the diagnosis segment. Sjogren’s Syndrome is a chronic autoimmune disease that causes dry eyes and mouth. For diagnosing Sjogren’s Syndrome, several tests are conducted including blood tests, saliva tests, lip biopsy etc. Among these, blood tests assessing autoantibodies levels such as anti-SSA/Ro and anti-SSB/La antibodies are the most common and established method for diagnosing Sjogren’s Syndrome. This is because the presence of these antibodies in blood strongly indicates Sjogren’s Syndrome. The diagnosis segment holds the major market share as detecting the presence of these autoantibodies is critical for diagnosing the disease at an early stage and started timely treatment.

PEST Analysis

Political: The government policies supporting funding for research on rare diseases including Sjogren’s Syndrome are positively impacting the market. Various laws and acts like the Orphan Drug Act provide incentives to pharmaceutical companies to develop drugs for rare and neglected diseases.
Economic: Rising healthcare expenditure driven by increasing incidence of the disease and growing awareness is fueling the market growth. Additionally, higher disposable income has increased patient affordability for advanced diagnostic tests and biologic drugs.
Social: Growing social media influence is increasing awareness about signs and symptoms of Sjogren’s Syndrome. Also, various foundations and support groups working towards patient education are encouraging early diagnosis and treatment seeking behavior.
Technological: Introduction of advanced diagnostic techniques like salivary scintigraphy and ultrasonography for detecting glandular involvement are enhancing accuracy of diagnosis. Furthermore, development of novel therapeutics pipelines targeting specific disease pathways offer promising treatment options.

Key Takeaways

The global Sjogren’s Syndrome Market Growth is expected to witness high growth supported by increasing awareness and diagnostic rates.

Regionally, North America holds the major market share currently due to developed healthcare infrastructure and high adoption of advanced diagnostic techniques in the region.
Europe is also a significant market driven by supportive government reimbursement policies and large patient population. However, Asia Pacific is emerging as the fastest growing market due to rising medical tourism, improving access to diagnosis and treatment, and growing focus of key players towards developing economies.

Key players

operating in the Sjogren’s Syndrome market are Allergan, Amneal Pharmaceuticals, AstraZeneca, Horizon Therapeutics, Novartis, Pfizer, Santen Pharmaceutical and Takeda Pharmaceutical. Companies are engaged in partnerships, new product launches and regulatory approvals to strengthen their market position.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it